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ORIGINAL ARTICLE
Rotavirus infection is the leading cause of acute
gastroenteritis and is responsible for most diar-
rhea-related hospitalizations and deaths among
infants and young children worldwide. Annually,
it is responsible for approximately 50,000 hospi-
talizations and 20 deaths in the United States
and 440,000 deaths worldwide.1 For this reason,
the development of an effective rotavirus vaccine
has been targeted as a public health priority.
Rotavirus commonly attacks children between
the ages of 6 and 24 months, and virtually all
children are estimated to be infected during the
first 3–5 years of life.2 Longitudinal studies have
demonstrated that naturally acquired rotavirus
infections provide protection against subsequent
rotavirus reinfection and protection is greatest
against severe disease.3 This observation supports
the concept that immunization can provide im-
munity against infection.
Rotaviruses are classified into types based on
two outer capsid proteins: G protein and P protein.
Both G and P proteins are immunogenic and
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Background/Purpose: Rotavirus infection is the most common etiology of acute gastroenteritis in young
children worldwide. The first rotavirus vaccine was licensed by the United States Food and Drug
Administration in 1998 but was suspended soon after in 1999 because of the possibility of induced intussus-
ception. This study evaluated the safety and immunogenicity of a newly developed pentavalent rotavirus
vaccine in Taiwanese children.
Methods: This was a phase III global trial designed to evaluate the safety and immunogenicity of an oral,
live pentavalent rotavirus vaccine (RotaTeq™). Taiwan was the only site in Asia enrolled in this trial.
Normal healthy infants aged 6–12 weeks were enrolled, and each of the subjects received either three oral
doses of the vaccine or placebo solution. The safety of the vaccine, particularly the risk of intussusception,
and immunogenicity were studied.
Results: A total of 189 infants were enrolled. No increased risk of intussusception or other adverse reactions
were noted following the vaccination. RotaTeq™ was immunogenic among subjects enrolled in Taiwan. At
least a three-fold rise in serum antirotavirus IgA antibody was found among 93% of the vaccine group. 
The immunogenicity of RotaTeq™ in Taiwan was comparable to that in other areas.
Conclusion: The pentavalent human-bovine vaccine, RotaTeq™, was safe, generally well-tolerated, and 
immunogenic among Taiwanese infants. [J Formos Med Assoc 2009;108(4):280–285]
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correlated with protection against rotavirus dis-
ease.4 The four most prevalent genotypes that 
account for > 80% of cases of human rotavirus
diarrhea worldwide are: G1P[8], G2P[4], G3P[8],
and G4P[8].5
The first rotavirus vaccine, Rotashield, was li-
censed in the United States in 1998. However, the
US Centers for Disease Control and Prevention
recommended suspending its further use soon
after because of a link between this vaccine and
increased risk of intussusception.6–8
RotaTeq™, a pentavalent rotavirus vaccine, is a
live vaccine constructed from an attenuated
bovine WC3 rotavirus, in which genes coding for
serotype-specific surface protein have been replaced
by genes from human rotavirus coding for the
comparable serotypes G1, G2, G3, G4 or geno-
type P[8]. These reassortant viruses induced im-
mune responses to the human capsid proteins
while maintaining the attenuation properties of
the parent strains. The safety, efficacy and immu-
nogenicity of the vaccine have been evaluated in
several phase I and II clinical trials.1
Methods
Study design
This was a Phase III, multicenter, randomized,
double-blind, placebo-controlled global trial de-
signed to evaluate the safety and immunogenicity
of the RotaTeq vaccine (Merck & Co., Inc.,
Whitehouse Station, NJ, USA). Taiwan was the
only site in Asia in this vaccine trial. Healthy 
infants between 6 and 12 weeks of age were 
enrolled from three hospitals in Taiwan.
The aims of this study were: (1) to assess the
safety of the rotavirus vaccine with respect to all
adverse effects (AEs) within 42 days of any dose
of vaccine; (2) to assess the incidence of intus-
susception occurring within 42 days of any dose
of vaccine and 1 year after the first dose; and (3)
to evaluate the immunogenicity of the three-dose
regimen of oral rotavirus vaccine in Taiwanese
children, and compare the results with those in
other countries.
Vaccination
The live pentavalent rotavirus vaccine was com-
posed of five human-bovine reassortant rotavi-
ruses, each of which contained the WC3 bovine
strain backbone with different human viral sur-
face proteins G1, G2, G3, G4 and P[8]. An esti-
mated final concentration of 6.5 × 107 IU to
1.2 × 108 IU was included in a 2 mL dose solu-
tion. Enrolled subjects were randomized to re-
ceive three oral doses of the vaccine or placebo at
three separate visits scheduled 4–10 weeks apart.
The first dose was administered between 6 and
12 weeks of age. Exclusion criteria are listed in
Table 1. Subjects who were receiving oral polio-
virus vaccine during the study or within 42 days
prior to the first dose of vaccine/placebo were
also excluded.
Immunogenicity evaluation
Antibody response to this vaccine was evaluated
in a subgroup of subjects recruited at the National
Taiwan University Hospital. Two serum samples
were collected for immunological evaluation.
Table 1. Infants with one of the following
conditions were excluded from this study
Exclusion criteria 
• Congenital abdominal disorders
• History of intussusception or abdominal surgery
• Impairment of immunological function
• Known history of hypersensitivity to any 
component of the rotavirus vaccine
• Prior administration of any rotavirus vaccine
• Fever at the time of immunization
• Prior rotavirus disease
• Chronic diarrhea
• Failure to thrive
• Active gastrointestinal illness
• Receipt of intramuscular, oral, or intravenous 
corticosteroid treatment
• Residence in a household with an 
immunocompromised person 
• Prior receipt of any blood transfusion or 
blood products
• Receipt of oral poliovirus vaccine during the 
course of the study or within 42 days prior to the 
first dose of vaccine/placebo
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One was collected before dose 1 of RotaTeq/
placebo, and the other was collected on day 42
after dose 3. Serological response was tested for
antirotavirus IgA antibody against WC3 by ELISA,
and for serum neutralizing antibody (SNA) against
rotavirus serotypes G1, G2, G3, G4 and P[8] by
an antigen-reduction enzyme immunoassay at
Cincinnati Children’s Hospital Medical Center
(Cincinnati, OH, USA), as reported previously.9–12
Seroconversion was defined as a greater than
three-fold increase in the antibody titer of either
antirotavirus IgA or NA.
Safety measurement
To evaluate the safety of the vaccine, all subjects
were followed for AEs for 42 days after each dose.
For the incidence of intussusception, they were
followed for 42 days after each dose and for up
to 1 year after the first dose. Intussusception was
defined by radiographic or surgical confirma-
tion, or evidence of intussusception at autopsy
within 1 year of the first dose.
Results
From April 2003 to June 2004, a total of 189 in-
fants (99 males, 90 females) were enrolled from
three hospitals in northern Taiwan. Of these, 96
were in the vaccine group, and 93 were in the
placebo group. Four children from the vaccine
group were withdrawn from the study during 
follow-up (3 were lost to follow-up and the other
was cross-treated).
The AEs of special clinical interest, such as
fever, intussusception, diarrhea, vomiting, and
irritable crying, are shown in Table 2. There were
no cases of intussusception in this Taiwanese co-
hort. During the 42 days of follow-up after each
vaccination and 1 year following the first dose,
the vaccine did not increase the risk of any AE in
comparison with the placebo group.
Seroconversion rates of antirotavirus IgA
were 93.9% (95% CI, 83.1–98.7%) among 49
vaccine recipients and 12.5% (95% CI, 4.7–
25.2%) among 48 placebo recipients (Table 3).
Seroconversion rates of SNA to each human ro-
tavirus serotype in the vaccine were signifi-
cantly higher in the vaccine group than in the
placebo group. At least a three-fold rise in SNA
titer against serotypes G1, G2, G3, G4 and P[8]
was found in 83.7%, 16.3%, 16.3%, 70.8% and
61.2% of patients, respectively, in the vaccine
group. In contrast, the seroconversion rates were
only 2.1–4.1% in the placebo group (Figure).
Discussion
According to the results of the large-scale
Rotavirus Efficacy and Safety Trial (REST) of
RotaTeq™, this vaccine was safe and efficacious in
preventing rotavirus gastroenteritis, and decreas-
ing severe diarrhea and health care-related con-
tact.13 Its efficacy was 74% against G1 to G4
rotavirus gastroenteritis of any severity, and 98%
against severe rotavirus gastroenteritis. The safety
substudy of the present trial showed that the
Table 2. Subjects in the Taiwan cohort with adverse events (AEs) of special clinical interest within 42 days
following any vaccination*
AE Vaccine (n = 95)† Placebo (n = 93) p‡
Fever§ 51 (53.7) 53 (57.0) 0.649
Intussusception 0 (0) 0 (0) –
Diarrhea 25 (26.3) 14 (15.1) 0.057
Vomiting 8 (8.4) 7 (7.5) 0.821
Irritable crying 1 (1.1) 1 (1.1) 0.988
*Data presented as n (%); †one subject was excluded from the vaccine group because of cross-treatment; ‡data analyzed by χ2 test;
§fever refers to all reported episodes of fever (rectal temperature > 38.0°C).
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rates of fever, vomiting and diarrhea within 42
days after any dose of vaccine were similar be-
tween the vaccine and placebo groups.
The results of our study demonstrate that the
vaccine is generally well-tolerated among normal
healthy infants in Taiwan. There was no case of
intussusception found in this study. It is expected
that the reassortant rotavirus vaccine will be safe
and effective in the prevention of severe illness
caused by rotavirus in Asia. However, the number
of cases in this study was too small to conclude
that this rotavirus vaccine was free from the risk
of intussusception.
According to a previous study, the protection
provided by primary rotavirus infection is serotype
specific.14 G1 rotavirus is now more prevalent
around the world;4,5 however, the predominant
circulating strains still vary by year and location.
The four G serotypes contained in the present
vaccine are responsible for > 80% of cases of ro-
tavirus gastroenteritis worldwide.5 Serotype G9
(in association with P[8]) has become more
prevalent during the past few years, especially in
some developing countries of Asia and Africa.5
Serotype G8 rotavirus has also emerged as an 
important serotype in some Africa countries.15
A sentinel hospital surveillance for rotavirus
diarrhea in Taiwan during 2001 to 2003 has
demonstrated that rotavirus accounted for 43%
of the hospitalizations for diarrhea among chil-
dren aged ≤ 60 months.16 The novel genotype
G9P[8] was detected most commonly (37% of
strains), followed by G1P[8] (31%), G2P[4]
(9.3%), and G4P[8] (3.7%).
The emergence of serotype G9 in Taiwan
since 2001 is of concern because it is not known
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Figure. Seroconversion rates for serum neutralizing antibody
(SNA) against human serotypes included in the vaccine.
Seroconversion was defined as a greater than three-fold
increase in the titer of SNA against each rotavirus serotype
between baseline and 42 days after the third dose.
Table 3. Immunogenicity for serum antirotavirus IgA response in 100 infants who received three doses of
RotaTeq or placebo
Vaccine Placebo
Predose 1 vaccination
Number of subjects 49 51
GMT (U/mL) of serum antirotavirus IgA 0.4 0.4
95% CI 0.2, 0.7 0.2, 0.8
Postdose 3 vaccination
Number of subjects* 49 48
GMT (U/mL) of serum antirotavirus IgA 305.6 1.3
95% CI 185.1, 504.4 0.6, 2.8
Seroconversion
Number of subjects* 49 48
Number (%) of subjects with ≥ 3-fold rise 46 (93.9) 6 (12.5)
in serum antirotavirus IgA 
95% CI 83.1%, 98.7% 4.7%, 25.2%
*Excludes subjects with invalid data based on laboratory determinations, or with samples taken out of 37 to 61 postdose 3 day range.
CI = confidence interval; GMT = geometric mean titer.
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whether or not it can also be protected against by
this pentavalent vaccine. A reassortant virus that
contained P[8] protein was included in the vaccine
because it is the most common circulating P pro-
tein and is usually combined with G1, G3, G4
and G9 serotypes. The REST study of RotaTeq™
has proven that the vaccine reduces related hos-
pitalizations and emergency department visits
caused by G9 rotavirus by 100%. The efficacy
against G9 rotavirus gastroenteritis of any severity
was 65.4%.13
However, because of the complexity and flexi-
bility of viral genotype diversity and epidemiology,
it is important that continued rotavirus strain
surveillance programs are conducted throughout
the world before and after the introduction of this
new vaccine.17 Ongoing surveillance also allows
for evaluation of vaccine impact once it has been
introduced in a country.
Measurement of serum antibody titers is a
common method for determining the immune
status of humans or animals against particular
microorganisms, including viruses. High titers
of serum antirotavirus IgA have shown a good
correlation with protection in children pre-
exposed to natural infection. However, no such
correlation of protection has been found for the
oral rotavirus vaccine.18,19 In fact, no specific titer
of any antibody analyzed has been established as
an immunological marker of protection after
vaccination.9,20,21 Their presence is a general in-
dicator for the actual effector of local protection,
e.g. virus-specific secretory IgA at the intestinal
mucosal surface, which is a critical factor for
protection.22
The seroconversion rates for SNA against G2
and G3 were low (both 16.3%) in comparison to
G1 and G4 (83.7% and 61.2%) in the present
study. A similar finding was also noted in the REST
study.13 However, the clinical efficacy against ro-
tavirus gastroenteritis of any severity according
to G serotype in the REST study was 74.9%,
63.4%, 82.7% and 48.1% for G1, G2, G3 and
G4, respectively. The serum antibody responses
following vaccination are only partially related
to protection.9 The relatively poor correlation
between serotype-specific SNA and clinical vac-
cine efficacy may be a real problem in the future,
when further evaluation of the vaccine effect on
various virus serotypes is needed.
In Taiwan, rotavirus gastroenteritis still leads to
significant morbidity in infants and children. One
out of every two to five children aged <5 years old
was estimated to require medical care for rotavirus
infection in Taiwan in 2001, with an estimated an-
nual medical expenditure of US$10–16 million.23
The application of rotavirus vaccine in infants
should be advantageous in Taiwan. However, be-
cause of the high vaccine prices, further study to
evaluate the health and economic benefits of uni-
versal infant rotavirus vaccination is needed.
In conclusion, the results of our study demon-
strate that this vaccine is safe and immunogenic
in healthy infants in Taiwan. Continued surveil-
lance is recommended.
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